Form 4: Nurix Director Granted 50,000 Stock Options

Nurix Therapeutics Director Roger D. Dansey was granted 50,000 stock options with an exercise price of $12.52, vesting monthly over three years.

Summary

• Roger D. Dansey, a Director of Nurix Therapeutics, Inc. (NRIX), was granted 50,000 stock options.
• The options have an exercise price of $12.52 per share.
• The transaction date for this grant was November 6, 2025.
• The options begin vesting on December 6, 2025, at a rate of 1/36th of the total shares monthly.
• Full vesting is scheduled for November 6, 2028, contingent on Mr. Dansey's continued service.
• The options expire on November 6, 2035.
• Following this transaction, Mr. Dansey beneficially owns 50,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a standard compensation event (stock option grant) for a director, which is generally viewed as a neutral to slightly positive event as it aligns insider interests with shareholders, without indicating any immediate operational or financial performance changes.

Positives

• The grant of 50,000 stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration date (November 6, 2035), providing a long-term incentive horizon.

Negatives

• No direct negatives are presented in this Form 4 filing, as it primarily reports a compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedule indicates an expectation of continued service from Director Roger D. Dansey until at least November 6, 2028, to fully realize the benefit of the stock option grant.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Nurix Therapeutics, Inc., to attract and retain talent, and to align the interests of directors with long-term shareholder value creation. This practice is widely adopted across publicly traded companies as a component of executive and director compensation packages.

Comparison to Industry Standards

• The grant of stock options to a director with a multi-year vesting schedule and a 10-year expiration period is consistent with standard compensation practices observed in the biotechnology sector.
• Similar equity compensation structures are common at peer companies such as CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA), where directors and executives often receive stock options or restricted stock units that vest over several years to ensure long-term commitment and performance alignment.
• The exercise price being set at the market price on the grant date is also a standard practice for incentive stock options.

Related Party Transactions

• The grant of 50,000 stock options to Roger D. Dansey, a Director of Nurix Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the issuer to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value. However, the exercise of these options in the future could lead to a slight dilution of existing shares.
• Employees: While this specific filing pertains to a director, such compensation practices generally reflect the company's overall approach to incentivizing key personnel, which can positively impact employee morale and retention.

Next Steps

• Continued provision of service by Roger D. Dansey to the Issuer to fulfill vesting conditions for the stock options.

Key Dates

Keywords

Nurix Therapeutics, NRIX, stock options, director compensation, insider transaction, Form 4, equity grant